The demonstration that angiogenic growth factors can stimulate new blood vessel growth and restore perfusion in animal models of myocardial ischemia has led to the development of strategies designed for the local production of angiogenic growth factors in patients who are not candidates for conventional revascularization. The results of recent clinical trials of proangiogenesis gene therapy have been disappointing; however, significant limitations in experimental design, in particular in gene transfer strategies, preclude drawing definitive conclusions. In the REVASC study cardiac gene transfer was optimized by direct intramyocardial delivery of a replication-deficient adenovirus-containing vascular endothelial growth factor (Ad-VEGF121, 4 Â 10 10 particle units (p.u.)). Sixty-seven patients with severe angina due to coronary artery disease and no conventional options for revascularization were randomized to AdVEGF121 gene transfer via mini-thoracotomy or continuation of maximal medical treatment. Exercise time to 1 mm ST-segment depression, the predefined
Introduction
Coronary artery disease (CAD) remains the leading cause of morbidity and mortality in the Western world. 1 The development of effective surgical and interventional procedures to revascularize the coronary circulation has had a major impact on the quality of life and survival for many patients with severe symptomatic CAD. However, despite these significant advances in treatment, there remain a number of patients with debilitating anginal symptoms who are refractory to maximal medical treatment, and are not candidates for mechanical revascularization. 2 Therapeutic angiogenesis may represent a novel treatment option for these patients. 3 Angiogenesis is a complex process that is orchestrated by an array of cytokines and growth factors, of which vascular endothelial growth factor (VEGF) is of para-mount importance. The VEGF family includes three separate genes (A, B and C). 4, 5 VEGF-A interacts with both VEGF receptor-1 (VEGFR1 or Flt-1) and -2 (VEGFR2 or KDR), and is essential for normal vasculogenesis during embryogenesis, such that even haploinsufficiency results embryonic lethality. 6 There are a number of different splice variants of VEGF-A (i.e. 189, 165 and 121 kDa) which differ in their affinity for extracelluar matrix. 3, 4 VEGF121, which lacks completely the heparinbinding domain, is the most freely diffusible and thus may be the best suited for cardiac proangiogenesis gene therapy. 4 Despite tremendous interest in the development of proangiogenesis therapies for patients with refractory anginal symptoms, as yet no randomized trial has provided definitive proof of clinical efficacy. However, this lack of success may reflect deficiencies in the delivery or transfection strategies that were used, rather than be evidence of true failure of therapeutic angiogenesis per se. For instance, the early trials used intracoronary or intravenous injection of protein factors, and poor cardiac uptake and limited stability of these growth factors within the myocardium may have contributed to the lack of significant biological activity. 7, 8 Similarly, randomized gene therapy trials have either lacked efficient transfection strategies or again relied on intracoronary delivery despite concerns from preclinical studies about the ability of this delivery strategy to effectively transduce the myocardium. AdVEGF121, a replication-deficient adenoviral vector carrying the transgene encoding for VEGF121, has been shown to produce angiogenesis when injected directly into the myocardium in a number of different animal models [10] [11] [12] [13] resulting in increased collateral blood flow to ischemic myocardium and improved cardiac function. In addition, a phase 1 clinical trial in patients with severe CAD and intractable angina pectoris demonstrated that intramyocardial injection of AdVEGF121 was well tolerated, and provided some early indication that this therapy could reduce myocardial ischemia. 14, 15 Therefore, the Randomized Evaluation of VEGF for Angiogenesis (REVASC) study was designed to compare the efficacy and safety of AdVEGF121, administered intramyocardially via a thoracotomy, with maximal medical treatment in patients with severe angina pectoris and no other options for revascularization.
Results

Patients
Of the 67 patients enrolled, 35 continued maximum medical treatment and 32 received AdVEGF121. As shown in Table 1 , the groups were well matched, except that the AdVEGF121 group had a significantly higher rate of diabetes and previous percutaneous coronary interventions. If anything, this imbalance would bias against a benefit with VEGF gene therapy, since diabetes and other coronary risk factors reduce angiogenesis. 16 There were no significant differences between groups with regard to the baseline exercise parameters (Table 2) .
Exercise parameters
Exercise parameters are shown in Figure 1 . While there was no significant difference between groups in time to 1 mm additional ST-segment depression at week 12, the AdVEGF121 group demonstrated a robust, statistically significant improvement in time to exercise-induced ischemia at week 26 (P ¼ 0.026). Total exercise duration and time to level 2 angina were also significantly improved in the AdVEGF121 group compared to control at weeks 12 (P ¼ 0.008 and 0.006) and 26 (P ¼ 0.015 and 0.003).
Rate-pressure product was measured at peak exercise, and at onset of level 2 angina, and onset of 1 mm STsegment depression. At each time point, change from baseline in rate-pressure product was greater in the AdVEGF121 group as compared to control, but this only achieved statistical significance for onset of level 2 angina at week 12 (P ¼ 0.027).
Anginal symptoms
Significant improvements in the Canadian Cardiovascular Society (CCS) class in the AdVEGF121 group as compared to control were apparent as early as 6 weeks and continued to improve at 12 and 26 weeks (Po0.001 (Figure 2 ). Patient self-assessment of symptomatology, as captured by the SAQ, showed significant improvements in all five domains (angina stability, angina frequency, disease perception score, treatment satisfaction and physical limitation) at all time points (6, 12 and 26 weeks), with the exception of physical limitation at week 6, which showed a nonsignificant trend ( Figure 3 ).
99m Tc-sestamibi single photon emission computerized tomography perfusion scans
Single photon emission computerized tomography (SPECT) scans were evaluated at baseline and at least one follow-up for 25 control patients and 25 AdVEGF121 patients. Scans for the remaining six patients included in the modified intent-to-treat (MITT) population were either not carried out (four patients) or not analyzable due to technical issues (two patients). No significant changes in perfusion scans were seen in the AdVEGF121-treated patients at 12 or 26 weeks. Paradoxically, week 26 results were in favor of the control group in summed stress score (19% reduction versus 4% reduction in the AdVEF121 group, P ¼ 0.044). It is unknown whether sestamibi injections were truly given at matched heart rates and thus, whether external workloads were well matched between groups. Rate-pressure product data indicates that the AdVEGF121 group reached a higher workload, and these patients were known to have longer walking times at follow-ups as compared to baseline. There were no significant differences in any other parameters at any other time points between the AdVEGF121 group and the control group.
Evidence of neovascularization on autopsy
One patient died from cardiogenic shock, secondary to a peri-operative myocardial infarct, 19 days after administration of AdVEGF121. Immunostaining at autopsy showed robust neovascularization in regions of the left ventricle corresponding to the site of the injections of AdVEGF121, with what appeared to be fairly mature vascular structures, endowed with a smooth muscle coat ( Figure 4 ). In contrast, the non-injected right and left ventricle showed no evidence of neovascularization. 
Safety and tolerability
Serious adverse events (SAEs) are summarized in Table  3 . The incidence of SAEs was similar between groups. As would be expected, a number of minor adverse events specifically related to the surgical procedure and general anesthesia occurred early in the AdVEGF121 group; however, there were otherwise no significant differences in incidence of adverse events or systematic drug-related laboratory abnormalities during follow-up. Interestingly, in the AdVEGF121 group, most major cardiac events occurred within 3 weeks of thoracotomy, whereas those in the control group occurred throughout the follow-up period. Urine and throat swabs for adenoviral cultures evaluated at approximately day 7 for 23 of the VEGFtreated patients were all negative. There were no significant differences in the ophthalmologic findings during follow-up. Seven control patients and six patients in the AdVEGF121 group developed new or worsening abnormalities, the majority of which were deemed clinically nonsignificant. Only one patient exhibited evidence consistent with diabetic retinopathy, and that patient received AdVEGF121.
Discussion
The REVASC study is the first major, randomized, controlled study to assess the potential efficacy of intramyocardial administration of an adenoviral vector encoding for an angiogenic factor as the sole therapy in patients with severe CAD and refractory angina. We now report that intramyocardial gene transfer of AdVEGF121 resulted in a significant increase in exercise time to 1 mm ST-segment depression, an objective measure of exerciseinduced ischemia, as well as subjective improvements in anginal symptoms and various quality of life measures. Despite the inability to blind for treatment assignment, these data provide some of the first support for the efficacy of therapeutic angiogenesis in patients with severe anginal symptoms who are not candidates for traditional revascularization procedures. The lack of blinding, a necessary consequence of using a thoracotomy to expose the heart and guide therapy, was counterbalanced by the certainty that the transgene was delivered into the myocardium in the ischemic zones. The intramyocardial delivery of the vector at an effective dose is an important strength that distinguishes this study from earlier randomized trials. Although, previous randomized trials using angiogenic growth factor proteins or genes in patients with CAD have failed to show clear evidence of benefit, these have suffered from serious methodological limitations which may have influenced the results. The FIRST 17 and VIVA 18 studies evaluated delivery of the growth factor proteins, fibroblast growth factor-2 (FGF2) and recombinant human VEGF, respectively. The lack of any clinical benefit in exercise tolerance was likely due to poor uptake of these protein factors from the coronary circulation and their short half-life, and thus, limited duration of activity of protein therapy. 7, 8 Delivery of these proteins was also associated with dose-related toxicities resulting from systemic exposure, thus limiting the amount of growth factor that could be safely administered.
Gene therapy provides the advantage of sustained production of the growth factor for up to 2 weeks after delivery of the DNA vector, depending on the nature of the vector and transfection strategy. The AGENT study, 19 which delivered an adenoviral vector containing FGF4 via intracoronary infusion, was the first randomized control trial for cardiac angiogenesis gene therapy, but again failed to show statistically significant clinical benefit in the treated group. However, this trial also used a intracoronary gene delivery strategy, which although convenient clinically, may result in inefficient Phase 2 randomized, controlled trial of AdVEGF 121 DJ Stewart et al uptake of the viral vector by the myocardium. 9 As well, this trial included a substantial number of CCS class 2 patients exhibiting good exercise tolerance even at baseline, making it difficult to demonstrate further benefit. Indeed, a predefined subset analysis excluding patients that could perform exercise for greater than 10 min by the Balke protocol did suggest significant benefit in the gene therapy group.
The REVASC study was designed to overcome the limitations of previous proangiogenesis trials. Thus, an intramyocardial gene therapy approach using a viral vector was employed to maximize transfection efficiency and induce sustained increases in growth factor production for a sufficient period to initiate the angiogenesis cascade. The dose of adVEGF121 was carefully chosen based on preclinical safety and efficacy data. Moreover, rather than injecting the vector into the coronary circulation, we used direct intramyocardial injection into all accessible myocardial regions under surgical control to achieve reliable delivery to the myocardium. However, a significant limitation of the REVASC trial was the lack of ability to blind patients and investigators with respect to treatment group due to the need for a surgical minithoracotomy to deliver the angiogenic agent. Recognizing the well-known placebo effect in this patient population with regard to both exercise parameters and symptomatic assessments, 20 we chose an objective primary end point, exercise time to 1 mm ST-segment depression. This end point is clinically relevant and has sufficient sensitivity and reproducibility to demonstrate a difference between groups given the limited sample size of this study. Moreover, to avoid observer-dependent bias, all exercise data were assessed in a blinded fashion by a central core laboratory. With these provisions in place, the observed difference between the AdVEGF121 and the control group is unlikely to be due to placebo effect. Of interest, significant improvement in this end point was seen only after 6 months, which suggests that neovascularization of ischemic myocardium may require a sufficient period of time to be fully manifested, especially in an older population with multiple coronary risk factors known to blunt the angiogenic response. 16 This conclusion is also supported by late improvement in angina class in the VIVA study, 18 and suggests that the objective benefit in functional status after VEGF gene therapy may be relatively sustained, providing an additional argument against the interpretation that this finding can be ascribed solely to a placebo effect. Another limitation of the study was the lack of ability to control for the effects of sham myocardial injections. Although we cannot exclude that needle damage alone may have contributed to enhance neovascularization in the AdVEGF121 group, the lack of convincing benefit seen in trials of direct endomyocardial laser revascularization makes this unlikely. 21 In contrast to the ST-segment analysis, there was no improvement in myocardial perfusion in the Ad-VEGF121-treated group by SPECT nuclear imaging. Although SPECT imaging can detect large changes in blood flow such as those observed following mechanical revascularization of epicardial coronary arteries, it has yet to be proven a useful measure of angiogenesis in the clinical setting. The limitations of SPECT imaging, including poor spatial resolution and reproducibility especially when using visual grading, have previously been described. 22, 23 Given this inherent variability, it is likely that a far greater number of patients would be needed to detect the smaller changes in myocardial Phase 2 randomized, controlled trial of AdVEGF 121 DJ Stewart et al perfusion achieved by proangiogenesis therapy. As suggested previously, other imaging modalities, including magnetic resonance perfusion imaging or positron emission tomography imaging, may be more suitable for the detection of these angiogenic effects. 22, 24 Curiously, an improvement was seen in the control group; this unexpected finding may be due to the fact that VEGFtreated patients exercised longer than the control patients in the follow-up tests, which resulted in a systematic bias against the treatment group.
Importantly, this study also provided the first anatomical support that intramyocardial injection of Ad-VEGF121 can result in new blood vessel formation in humans, as qualitative evidence of local neovascularization was seen in the myocardium of one patient who died 19 days after administration of AdVEGF121. Although treatment with AdVEGF121 was well tolerated, thoracotomy in this patient population was associated with substantial morbidity and some mortality. However, only three patients in the ADVEGF121 group, as compared to nine patients in the control group, experienced major cardiac events after the initial 3 weeks (Table 3) , possibly consistent with late benefits of therapeutic angiogenesis. Aside from procedure-related events associated with the thoracotomy, there was no significant difference in adverse events or laboratory safety tests between the two groups. Only one patient developed diabetic retinopathy, and, although this patient was in the VEGF gene therapy group, it must be noted that this group also had more than twice the number of patients with diabetes compared with the control group. As well, the only malignancy was a recurrent bladder cancer in a patient who had previously been treated for this condition and this was also a gene therapy patient. However, given the very low incidence of these events, no conclusions can be drawn regarding any causal relationship with AdVEGF121 therapy. Moreover, the absence of any evidence of significant pericardial effusion on serial echocardiography indicated that at least with the dose used in this study, the vascular permeability-enhancing effect of VEGF 24, 25 was not clinically relevant. Urine and throat swabs for adenoviral cultures recorded at day 7 were consistently negative, indicating that the virus was indeed replication deficient. This relatively benign adverse event profile is consistent with results from other clinical trials employing VEGF 14, 15, 18, 26 as well as FGF. 17, 19 Since this study was designed, several injection catheter systems have been developed that provide a safe and reliable method for percutaneous intramyocardial delivery. These catheters have been extensively tested in the clinic [27] [28] [29] demonstrating the feasibility of administering growth factors directly into the heart via a catheter. Animal studies have demonstrated equivalence in gene expression and protein secretion 30 regardless of whether AdVEGF121 is injected from the endocardial or epicardial side of the heart. The intramyocardial injection of plasmid DNA for VEGF165 using the MyoStart navigational injection catheter was recently reported to improve regional wall motion in the phase 2 randomized EUROINJECT ONE trial, 31 although there were no differences in stress-induced myocardial perfusion or improvement in symptom class. However, this study used a relatively low total dose of plasmid DNA (i.e. 500 mg) and clearly the overall efficiency of gene transfer would be considerably lower with the injection of naked DNA compared with adenoviral vectors used in the present study.
In conclusion, the REVASC study demonstrates that intramyocardial administration of AdVEGF121 was associated with significant improvement in symptoms and exercise capacity in patients with CAD already receiving maximal medical treatment. However, these results still need to be confirmed in a randomized, double-blind, placebo-controlled trial, preferably using an injection catheter to overcome the limitations of trial design inherent with the use of surgical delivery of gene therapy.
Materials and methods
Trial design
This was a randomized, controlled study, allocating patients to maximum medical therapy versus Ad-VEGF121 (4 Â 10 10 particle units (p.u.)) administered by direct intramuscular injection via a minithoracotomy. Efficacy assessments were performed up to 26 weeks, while safety evaluation was continued to week 52. The protocol was approved by the institutional review board (IRB) in each of the 16 participating institutions, the procedures followed were in accordance with institutional guidelines, and all patients provided written informed consent prior to undergoing study-specific procedures.
Patients
Patients were enrolled from January 2000 to March 2002 if they had angina refractory to maximum medical therapy defined as CCS Class II-IV symptoms despite the use of nitroglycerin, platelet aggregation inhibitors, and at least two of the following medications: long-acting nitrates, calcium-channel blockers and beta-blockers. Evidence of significant stenosis on coronary angiography involving at least two vessels (one with at least 70% narrowing) or a prior Q wave myocardial infarction and at least 70% stenosis in a vessel subserving another region was required for entry. Eligible patients were deemed not suitable for any other type of revascularization procedure after a review by a cardiovascular surgeon and an interventional cardiologist. In addition, patients had to be able to exercise for at least 90 s and no more than 8 min on an Asymptomatic Cardiac Ischemia Pilot (ACIP) 32 protocol exercise treadmill test (ETT), while at the same time exhibiting angina with additional 1 mm horizontal or downsloping ST-segment depression. Exclusion criteria included: age o18 or 480 years; pregnancy; acute coronary or cerebrovascular syndrome within 2 weeks; left ventricular thrombus and/or significant (490%) unprotected proximal left anterior descending stenosis and/or left main equivalent; electrocardiographic abnormalities that would interfere with ST-segment or T-wave analysis; uncontrolled hypertension or significant hypotension, defibrillator or implantable pacemaker; severe congestive heart failure; left ventricular ejection fraction o25%; significant uncorrected valvular disease; imminent or planned heart transplantation within 26 weeks; significant anemia, abnormal prothrombin or partial thromboplastin time (41.5 Â ULN), thrombocytopenia (platelet count 
AdVEGF121 transfer
The human VEGF121 transgene with a cytomegalovirus promoter enhancer was inserted into an E1a, and partially E1b and E3, -deleted adenoviral construct based on a replication-deficient adenovirus type 5 vector, and the vector was prepared as previously described.
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Patients randomized to AdVEGF121 therapy received a total dose of 4 Â 10 10 p.u., administered as 30 intramyocardial injections throughout the free wall of the left ventricle. The heart was accessed via a left thoracotomy 14 (p10 cm in length) under general anesthesia and injections (100 ml) were spaced at least 1.5-2.0 cm apart. The heart was notionally divided into 20 segments 33 with the 14 segments of the left ventricle free wall (excluding septal segments) being targeted for injection. Although each segment received at least one injection, investigators were able to preferentially target the remaining injections into regions identified as ischemic, based on all available clinical and diagnostic information, including the location of the ischemic zones on cardiac nuclear perfusion scans and distribution of coronary lesions by angiography.
Exercise test parameters
A symptom-limited ETT using the ACIP protocol 32 was performed at baseline and at 12 and 26 weeks. The primary end point was change from baseline at week 12 in time to onset of 1 mm additional ST-segment depression on exercise ECG. In the absence of such ST depression, time to termination of ETT was used. Exercise ECGs were evaluated by a central core laboratory (Washington University, St Louis, USA) blinded to treatment allocation. Secondary end points were time to 1 mm additional ST-segment depression at week 26, and total exercise duration, time to level 2 (moderate) angina, 34 and peak rate-pressure product (heart rate Â systolic blood pressure) on ETT at weeks 12 and 26.
SPECT myocardial perfusion
A Tc-99m sestamibi nuclear myocardial perfusion protocol was performed at rest and during exercise at baseline and at weeks 12 and 26. At the baseline stress tests, sestamibi injections were administered 1 min prior to maximum exercise. During follow-up assessments, the injections were to be given once patients reached the same heart rate at which injections were given at baseline. SPECT images were visually graded using a 20-segment left ventricular model 33 by a blinded central core laboratory (Cedars-Sinai Medical Center, LA, USA). SPECT imaging was performed using a standard 1801 acquisition starting at 451 RAO position. Tomographic acquisition was performed in 64 Â 64 matrix using step and shoot acquisition with storage in 31 intervals with low energy, high resolution collimation and circular orbit. A 15% window about the Tc-99m 140 Kev photopeak was utilized. Total acquisition time was 19 min. All studies were performed gated with eight images per cardiac cycle and with 100% beat acceptance. Summed stress score, global wall motion score (rest and stress), and summed reversibility (difference) score were predefined as secondary end points. Summed rest score, left ventricular ejection fraction, left ventricular end diastolic volume, extent of hypoperfusion, and percent myocardium with reversible and irreversible defects were also assessed.
Subjective assessments
Patient symptoms were assessed at baseline and after 6, 12 and 26 weeks by the investigator using the CCS Angina Classification and by patient self-assessment using the Seattle Angina Questionnaire (SAQ).
Safety assessments
Evaluations at entry included general physical exam and history (repeated at weeks 2, 6, 12, 26 and 52); rest electrocardiogram (repeated at weeks 12 and 26); holter, echocardiography and chest X-ray (repeated at week 12); and laboratory parameters including hematology and chemistries (repeated at weeks 6 and 12) and urinalysis and coagulation. Owing to concerns that VEGF gene therapy might stimulate pathological angiogenesis in non-target organs, 35 subjects were assessed for malignancy in accordance with the American Cancer Society guidelines at entry and at 12 and 52 weeks, and for retinal neovascularization at entry and at 26 weeks. Retinal exams were performed by on-site ophthalmologists using standardized protocols, 36 and standard field stereo color fundus photographs were sent to a central core lab for evaluation for all diabetic patients and in cases of suspected proliferative retinopathy.
Additional monitoring of the AdVEGF121-treated patients during the week of hospitalization following minithoracotomy included resting ECGs at 16 and 24 h post-administration and daily during hospitalization, cardiovascular enzymes (CPK, CPK-MB and troponin) at 8, 16 and 24 h post-dosing and daily during hospitalization, and chemistry and hematology at day 2. Chemistry, hematology, urinalysis, rest echocardiography, chest X-ray, and urine and throat swabs for adenoviral cultures were completed prior to discharge.
Statistical analysis
An analysis of covariance (ANOVA), using a MITT population, was performed to compare the effects of AdVEGF121 and maximum medical therapy on the change from baseline in the primary and secondary end points. Exclusions from the MITT analysis, as indicated in Table 4 , were predefined in the protocol and statistical analysis plan. The results of additional analyses were summarized descriptively.
